Skip to main content
. 2016 May;22(5):10.18553/jmcp.2016.22.5.526. doi: 10.18553/jmcp.2016.22.5.526

TABLE 1.

Member Demographics and Clinical Characteristics

Oral Antidiabetics, n = 5,421 Antihypertensives, n = 19,520 Statins, n = 19,244
Intervention Control P Value Intervention Control P Value Intervention Control P Value
Member count, n 1,277 4,144 4,787 14,733 4,382 14,862
Female, % 51.8 53.9 0.180 53.6 56.9 < 0.001 51.8 54.9 < 0.001
New to therapy,a % 21.5 22.4 0.484 20.9 20.0 0.155 21.8 19.4 < 0.001
90-day refill, % 59.6 70.0 < 0.001 64.4 71.6 < 0.001 65.7 72.8 < 0.001
Low-income subsidy, % 41.4 18.9 < 0.001 34.6 15.9 < 0.001 32.7 16.2 < 0.001
Age, years, mean (SD) 71.3 (8.8) 73.7 (8.7) < 0.001 71.8 (9.2) 74.6 (8.7) < 0.001 71.3 (8.5) 73.8 (8.5) < 0.001
Age group, years, % < 0.001 < 0.001 < 0.001
< 54 4.6 3.0 4.8 2.2 3.7 2.5
55-64 12.9 6.8 12.0 5.5 11.9 5.4
65-74 53.6 49.8 51.5 47.9 54.1 48.9
75+ 28.9 40.4 31.6 44.4 30.4 43.2
Number of target medication classes,b % 0.640 < 0.001 0.090
1 13.7 12.1 41.2 34.6 38.5 36.0
2 39.2 35.3 45.4 50.0 47.0 48.5
3 47.1 52.6 13.4 15.3 14.5 15.4
Comorbidity count,c % 0.161 0.008 0.078
< 3 29.8 30.9 41.7 42.1 45.6 44.2
3-4 40.5 40.6 35.3 35.9 31.9 34.2
5-6 20.8 20.5 16.7 16.0 16.1 15.4
7-8 6.6 6.5 4.8 4.8 5.0 4.9
9+ 2.3 1.5 1.5 1.2 1.6 1.3

aDefined as absence of prescription claim for targeted medication class in 1-year baseline (preintervention) period.

bMembers could be identified for intervention by more than 1 medication class.

cComorbidity count estimated by Medicaid Rx.